KUALA LUMPUR (Nov 23): Kanger International Bhd said it had received support from the Ministry of Science, Technology and Innovation (MOSTI) to purchase Covid-19 vaccines for private-sector use in Malaysia.
In a statement today, the company said the National Institutes of Biotechnology Malaysia (NIBM), an agency under MOSTI, had no objection for the company to liaise with China National Pharmaceutical Group Corp (Sinopharm) on the purchase of vaccines.
“As countries around the world work towards securing Covid-19 vaccine supplies, it is necessary for both the public and private sectors to join efforts.
“Just recently, the Malaysian and Chinese governments signed an agreement to foster greater collaboration in combating the Covid-19 pandemic, which includes cooperation in vaccine research and development (R&D) and supply,” said Kanger executive director Steven Kuah Choon Ching.
He said the company is pleased to receive the support from MOSTI and the NIBM as it demonstrates the government’s commitment to exploring all avenues to ensure Malaysians gain access to a vaccine.
On Sept 29, Kanger announced that it aims to venture into the distribution of Covid-19 vaccines and had signed a collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd, a subsidiary of Sinopharm, for the distribution of vaccines.
Sinopharm, a Chinese state-owned enterprise (SOE), is the largest and oldest biotech company in China.
It has developed two Covid-19 vaccines that have already entered Phase Three trials, the final stage before being approved for general use in more than 10 countries.